We conduc ted a retrospective study to eval uate the longterm effec tiveness of gentamic in applied directly to the round window membrane via the Silverstein MicroWick system in patients with definite or probable Meniere 's disease. The study population was made up of69 pati ents who had received 3 drops ofgentamicin Jamg/tnl three times daily; the duration of treatment was guided by objective data obtained from weekly electronystagmog raphy and audiometry. Relief of vertigo was assessed by chart review and telephone interviews. Af ter a minimum fo llow-up of 24 months , wefound that vertiginous symptoms remained controlled in 53 patients (76.8 %) after one or more courses ofdrug therapy.A single course oftreatment was successful in4 J patients (59 .4%). We conclude that long-term control ofvertigo can be achieved inpatients with Meniere sdisease by direct appl ication of genta mic in to the round window membrane via the Silverstein MicroWick. This minimally invasive self-treatment techniqu e was well tolerated and free of long-term complications.
Introduction
Schuknecht originally described middl e em' perfusion with an aminogly cos ide antibiotic for the treatment of Meni ere 's disease in 1956 . 1 Afterwa rd, the popularity of transtympanic methods of treating inner ear disease grew rapidl y. Transtymp anic treatment of Meniere's disease has several adva ntages : (l ) it is easy to perform , (2) the surgeo n ca n treat the affected ear directly, (3) dru g can be deli vered to the site of action in higher concentrations , (4) the side effect s of sys temic dru g ther apy are avo ided, and (5) these procedures are much less invasive than the traditional From Two types of transtymp anic ge nta mic in dosing schedules have been descri bed in the literature: fixed dosing and titrat ion . Th e titr ation metho d relies on objec tive measures obtained by electro nystag mog raphy (ENG) and audio met ry to guide therapy. Toth and Parn es co mpared the two meth od s and found that while they were equally effec tive, the titration method result ed in significantly less hearing loss. III Th e Sil ver stein MicroWi ck sys tem has been shown to be highl y successful in co ntro lling vertigo in patients with Men iere ' s disease. In 2002, our gro up rep orted the outcomes of 92 pat ient s who had been treat ed with 3 drop s of ge ntamicin 10 mg/ml three times daily.' Th e Sil verstein MicroWi ck sys tem deli vers ge nta micin in a titr ated fashion , and therefore treatm ent was guided by week ly ENG and audio metry res ults; the treatment goal wa s to elicit a 100 % reduced vestibular res po nse (RVR) to ice air on ca loric testing. Of patients who responded to a questionn aire, 85 % ex perience d reli ef of vertigo , 67% ex perienced allev iation of aura l pressur e, and 57 % ex perienced reli ef of tinnitus. Th e overall incid enc e of hear ing loss was 36 %. These results are ess entially the same as those repo rted by others.I I on In another study, we atte mpted to e luc ida te the relat ionsh ip betwe en the level of ves tibular ablatio n, the subsequent cont rol of vertigo, and the risk of hearin g loss with the MicroWick system.'
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ClTYIS"TATt/lIP: We did find an association among these variables, and we also suggested that it might not be necessary to elici t a 100% RVR in order to ac hieve or main tain vertigo control. In that study, the overall vertigo control rate was 82%, the ver tigo per sistence rate wa s 9%, and the vertigo recurrence rate was 9%. All recurrent episodes occurred wit hin I year.
Until now, no data have bee n published on long-term outcomes following the direc t app licat ion of gentamici n to the round wi ndow membrane via the Silvers tei n Micro-Wick sys tem in patients with Meniere's disease. Th e objec tive of this article is to repor t our eva luation of the MicroWick after a min imum of 24 month s' follow-up in terms of ver tigo control, the need for repeat treatment s, the management of treatment failures, and overall patie nt satisfaction. Th e current study is a fo llow -up to our two earlier studies. P recurrence, 21 underwent repe at gentamicin therapy and 7 wen t straight to surgery. Of the 21 patient s who repeated drug therapy, 12 (57. 1%) ultimately respo nded . Five of the remaining 9 underwent surgery, while the other 4 (5.8% of the entire study pop ula tion) conti nued to try repeat drug therapy to no avai l; 3 of these 4 patients subseq uent ly developed symptoms in the other ea r. By study's end, 53 of the 69 patients (76 .8%) achieved long-t erm vertigo control with one or more courses of gentamicin therapy.
In all, 12 patients underwent surgery. Th e spec ific procedures included 6 vesti bular nerve sec tio ns, 4 transca nal labyrinthectom ies, and 2 transmastoid labyrinthectomies. All 12 surgical patient s obtained relief of their vertigo symptoms.
Follow-up teleph one interv iews revealed that all 53 patients who respond ed to gentamicin therapy were either "sa tisfied" or "very satisfied" with the ir treatm ent.
Discussion
Th e findings ofour study reinforce the evidence support ing the role of gentamicin inner ear perfusion for the treatment of vertigo in patients with Men iere 's disea se. Specifically, the application of gen ta micin via the Sil verstein Micro-Wick syste m has bee n shown to be consistently effective. 
Patients and methods
We retrospectively reviewed the records of 92 patients with Meniere 's disease who had been treated at a private oto logy/neuroto logy practice with gentamicin inner ear perfusion via the Sil verstein MicroWick system. Patients had received 3 drops of gentamicin 10 mg/ml three times daily ; the duration of titrated treatment was guided by objective data obta ined fro m week ly ENG and audiometry, with a targeted endpoin t of a 100% RVR on ice air. Specific procedural aspec ts Table. Long-term results of the initia l treatment regi men have been -------------------------descr ibed in detail elsewhere.P In addition to patients' charts, telephone ca lls were also used to obtain data. A total of 69 patient s-23 men and 46 women, age d 27 to 92 years (mean: 70) at the time of follow up-met the inclusion cr iter ia for this study. Th ese criteria included (I) a diag nos is of Meniere's disease base d on the America nAcademy ofOto lary ngo logy-Head and Neck Surgery 's cr iteria for "definite" and "probable" Me niere' s disease, 14 (2) treatment with the M icroWick system, (3) co mpletion of treatment, and (4) a minim um follow -up of 24 months. 
Results
The length of follow -up ranged from 24 to 68 months. The initial treatment reg ime n res ulted in long-term vertigo contro l in 4 1 patie nts (59.4 %) (table) . Th e remai ning 28 patients (40 .6%) experienced at least one recurrence of vertigo between I and 40 months after the completio n of initial treatm ent.
Of the 28 patients who had experience d a HILL, DIGGES, SILVERSTEIN that they were "satisfied" or "very satisfied" with their treatment. These results are consistent with our previously published work, although the rate of recurrence over the longer follow-up period was slightly higher. >' > Even so , most of the recurrences were controlled with additional gentamicin treatments. Only 9 of the 69 patients (13 .0%) were unable to achieve vertigo control after repeated gentamicin treatments. It is possible that these patients had other etiologies (e.g. , autoimmune inner ear disease) that contributed to their vertigo symptoms. Critics of this treatment may cite natural history data on Meniere's disease as the reason for the good results reported herein.":" Although this may appear to be a valid criticism, most of the patients in this study who obtained long-term relief of vertigo did so within 3 months of treatment. Thi s treatment most likely decreases the number of vertigo recurrences as well as the length of time during wh ich patients experience recurrences. We believe that this treatment may prevent years of unnecessary suffering from unpredictable episodes of vertigo. Moreover, the possibility that this treatment may preserve residual hearing is an interesting topic for speculation. Further studies, both clinical and histopathologic, are necessary to further elucidate these issue s.
It is interesting to note that of the 12 patients (17.4 %) who eventually went on to surgical intervention, most (7) did so without first attempting additional gentamicin treatment. These 7 patient s may have been less tolerant of vertigo symptoms or more resistant to gentamicin treatment, or it is po ssible that their recurrent symptoms were more severe. Other authors have noted that the degree of RVR following gent amicin treatment is not uniform among patients. I? We also noted an element of unpredictability in eliciting RVRs in our study.
Of the 4 patients (5.8 %) who did not achieve long-term vertigo control, 3 later experienced a clinical course that was characterized by fluctu ating episodes of vertigo and hearing loss, multiple repeat treatments with gentamicin, temporary recovery of vestibular function after treatment, and more recurrences . These 3 patients sub sequently developed symptoms in the opposite ear, and they were tentatively diagnosed with bilateral Meniere's disease or autoimmune inner ear disease. Inretrospect, these patients might have been more effectively treated with steroid perfusion of the inner ear.
In conclusion, the optimal treatment paradi gm for Meniere' s dise ase has not yet been defined. Further study of both gentamicin inner ear therapy and the underlying pathogenesis of Meni ere's disea se may help contour future treatment. But in the meantime, gentamicin perfusion therapy via the Silverstein MicroWick system is a safe , inexpensive, and easy-to-self-administer option.
